Pfizer Corporation

Yoriko Ohashi

Fumitaka Ito

Hirohide Noguchi

Hiroshi Kondo

Tatsuya Yamagishi

Hirohisa Shimokawa

A compound of the formula:or a pharmaceutically acceptable salt thereof, wherein Ris unsubstituted, mono-, di- or tri-substituted (C-C)cycloalkyl or (C-C)cycloalkenyl or the like, A is unsubstituted (C-C)alkyl or (C-C)alkenyl, hydroxy-(C-C)alkyl, (C-C)alkoxy-(C&#x2550;O), or unsubstituted, mono-, di- or tri-substituted aryl, or aromatic-heterocyclic or the like, M is a covalent bond O, S, NH or the like, Y is 4- to 12-membered bicyclic-carbocyclic rings or 4- to 12-membered bicyclic-heterocyclic rings, or 5- to 17 membered spirocarbocyclic rings or 5- to 17-membered spiroheterocyclic rings or the like, Z, Z, Zand Zare hydrogen or the like, is disclosed. These compounds have ORL-receptor agonist activity, and are thus useful as analgesics or the like in mammalian subjects.

Benzimidazole compounds as ORL1-receptor agonists

1,3,8-Triuazaspiro(4,5)decanone compounds as ORL1-receptor agonists

4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists

Growing community of inventors

Chita-gun, Japan

Yoriko Ohashi